Garrido A, Brunet S, Calabuig M, et al. Final results of the CETLAM LAM-203 trial fort he treatment of primary AML up tot the age of 70. EHA 2017, abstract S790.
Navitoclax plus ruxolitinib bij myelofibrose: respons onafhankelijk van HMR-mutatiestatus
jul 2022 | MPN